Neuren Pharmaceuticals
Market Cap
AU$253.4m
Last Updated
2019/10/20 10:31 UTC
Data Sources
Company Financials +
Executive Summary
Neuren Pharmaceuticals Limited, a biopharmaceutical company, engages in the development of drugs for the treatment of chronic neurodevelopmental and neurodegenerative disorders, and acute traumatic brain injury.
Snowflake
Fundamentals
Flawless balance sheet with weak fundamentals.
Share Price & News
How has Neuren Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
8.6%
NEU
1.7%
AU Pharmaceuticals
0.4%
AU Market
1 Year Return
101.6%
NEU
-35.1%
AU Pharmaceuticals
9.8%
AU Market
Return vs Industry: NEU exceeded the Australian Pharmaceuticals industry which returned -35.1% over the past year.
Return vs Market: NEU exceeded the Australian Market which returned 9.8% over the past year.
Shareholder returns
| NEU | Industry | Market | |
|---|---|---|---|
| 7 Day | 8.6% | 1.7% | 0.4% |
| 30 Day | 27.5% | 2.2% | -1.1% |
| 90 Day | 80.7% | -1.5% | -0.6% |
| 1 Year | 101.6%101.6% | -34.9%-35.1% | 16.1%9.8% |
| 3 Year | 169.1%169.1% | -43.6%-44.1% | 36.1%17.9% |
| 5 Year | 52.4%52.4% | -17.3%-24.9% | 49.4%15.7% |
Price Volatility Vs. Market
How volatile is Neuren Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
Could Neuren Pharmaceuticals Limited's (ASX:NEU) Investor Composition Influence The Stock Price?2 months ago | Simply Wall St
What Is Neuren Pharmaceuticals's (ASX:NEU) P/E Ratio After Its Share Price Rocketed?4 months ago | Simply Wall St
Do Institutions Own Neuren Pharmaceuticals Limited (ASX:NEU) Shares?Valuation
Is Neuren Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
15.1x
Price to Book (PB) ratio
Share Price vs. Fair Value
Undervalued: Insufficient data to calculate NEU's fair value to establish if it is undervalued.
Significantly Undervalued: Insufficient data to calculate NEU's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: NEU is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: NEU is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
Low PEG Ratio: Insufficient data to calculate NEU's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NEU is overvalued based on its PB Ratio (15.1x) compared to the AU Pharmaceuticals industry average (3.1x).
Next Steps
Future Growth
How is Neuren Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
40.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NEU is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NEU is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NEU is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NEU's revenue is expected to decline over the next 3 years (-35.9% per year).
High Growth Revenue: NEU's revenue is forecast to decline over the next 3 years (-35.9% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
High Future ROE: NEU is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Neuren Pharmaceuticals performed over the past 5 years?
42.7%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: NEU is unprofitable, but has reduced losses over the past 5 years at a rate of 42.7% per year.
Accelerating Growth: Unable to compare NEU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NEU is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6%).
Return on Equity
High ROE: NEU has a negative Return on Equity (-4.27%), as it is currently unprofitable.
Return on Assets
ROA vs Industry: NEU is currently unprofitable, so its Return on Assets is negative.
Return on Capital Employed
ROCE Improving: NEU is currently unprofitable, so its Return on Capital Employed is negative.
Next Steps
Financial Health
How is Neuren Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: NEU's short term assets (A$18.1M) exceeds its short term liabilities (A$1.3M)
Long Term Liabilities: NEU has no long term liabilities
Debt to Equity History and Analysis
Debt Level: NEU is debt free.
Reducing Debt: NEU has not had any debt for past 5 years.
Balance Sheet
Inventory Level: NEU has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if NEU's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable NEU has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: NEU is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 92.5% per year.
Next Steps
Dividend
What is Neuren Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate NEU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate NEU's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if NEU's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NEU's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NEU's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
Next Steps
Management
What is the CEO of Neuren Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?
1.3yrs
Average board tenure
CEO
Neuren Pharmaceuticals has no CEO, or we have no data on them.
Board Age and Tenure
1.3yrs
Average Tenure
Experienced Board: NEU's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Company |
| Shares | 7,645 |
| Max Price | AU$3.27 |
| Entity | Company |
| Shares | 4,164,223 |
| Max Price | AU$1.40 |
Ownership Breakdown
Management Team
Larry Glass
Chief Science Officer
- Tenure: 15.8yrs
Jon Pilcher
CFO & Company Secretary
- Tenure: 6.2yrs
Richard Treagus
Executive Chairman
- Tenure: 6.8yrs
Board Members
Dianne Angus (59yo)
Independent Non-Executive Director
- Tenure: 1.3yrs
Trevor Scott
Independent Non-Executive Director
- Tenure: 17.6yrs
Jenny Harry
Independent Non-Executive Director
- Tenure: 1.3yrs
Richard Treagus
Executive Chairman
- Tenure: 6.8yrs
Patrick Davies
Independent Non-Executive Director
- Tenure: 1.3yrs
Company Information
Neuren Pharmaceuticals Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Neuren Pharmaceuticals Limited
- Ticker: NEU
- Exchange: ASX
- Founded: 1993
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$253.426m
- Shares outstanding: 100.17m
- Website: https://www.neurenpharma.com
Number of Employees
Location
- Neuren Pharmaceuticals Limited
- 697 Burke Road
- Suite 201
- Camberwell
- Victoria
- 3124
- Australia
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| NEU | ASX (Australian Securities Exchange) | Yes | Ordinary Shares | AU | AUD | Feb 2005 |
| NURP.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Feb 2005 |
| NEU | CHIA (Chi-X Australia) | Yes | Ordinary Shares | AU | AUD | Feb 2005 |
| NEU | CHIA (Chi-X Australia) | Yes | Ordinary Shares | AU | AUD | Feb 2005 |
Biography
Neuren Pharmaceuticals Limited, a biopharmaceutical company, engages in the development of drugs for the treatment of chronic neurodevelopmental and neurodegenerative disorders, and acute traumatic brain i ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/20 10:31 |
| End of Day Share Price | 2019/10/18 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.